ALVR
Price:
$0.5111
Market Cap:
$59.06M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly ...[Read more]
Industry
Biotechnology
IPO Date
2020-07-30
Stock Exchange
NASDAQ
Ticker
ALVR
According to AlloVir, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.58. This represents a change of -77.25% compared to the average of -2.55 of the last 4 quarters.
The mean historical PE Ratio of AlloVir, Inc. over the last ten years is -81.02. The current -0.58 PE Ratio has changed -28.41% with respect to the historical average. Over the past ten years (40 quarters), ALVR's PE Ratio was at its highest in in the December 2023 quarter at -0.32. The PE Ratio was at its lowest in in the March 2019 quarter at -105.81.
Average
-81.02
Median
-9.92
Minimum
-387.62
Maximum
-0.37
Discovering the peaks and valleys of AlloVir, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -0.37
Minimum Annual Increase = -84.06%
Minimum Annual PE Ratio = -387.62
Year | PE Ratio | Change |
---|---|---|
2023 | -0.37 | -84.06% |
2022 | -2.33 | -50.66% |
2021 | -4.72 | -68.76% |
2020 | -15.12 | -80.08% |
2019 | -75.92 | -80.41% |
The current PE Ratio of AlloVir, Inc. (ALVR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.48
5-year avg
-19.69
10-year avg
-81.02
AlloVir, Inc.’s PE Ratio is greater than Anebulo Pharmaceuticals, Inc. (-5.11), greater than Mineralys Therapeutics, Inc. (-4.33), greater than AN2 Therapeutics, Inc. (-0.70), greater than Aerovate Therapeutics, Inc. (-0.92), greater than Adagene Inc. (-2.78), less than Homology Medicines, Inc. (-0.01), greater than Stoke Therapeutics, Inc. (-7.35), less than Atreca, Inc. (-0.06), greater than Black Diamond Therapeutics, Inc. (-1.85), greater than 4D Molecular Therapeutics, Inc. (-2.78), greater than Acrivon Therapeutics, Inc. Common Stock (-3.29), greater than Cullinan Oncology, Inc. (-5.16), less than Agios Pharmaceuticals, Inc. (4.11), greater than Crinetics Pharmaceuticals, Inc. (-16.32), less than Inhibrx Biosciences, Inc. (0.14), greater than Merus N.V. (-12.21), greater than Lyell Immunopharma, Inc. (-1.13), greater than Kronos Bio, Inc. (-0.75), greater than AnaptysBio, Inc. (-3.99),
Company | PE Ratio | Market cap |
---|---|---|
-5.11 | $40.46M | |
-4.33 | $663.42M | |
-0.70 | $42.43M | |
-0.92 | $77.67M | |
-2.78 | $89.43M | |
-0.01 | $3.02M | |
-7.35 | $728.83M | |
-0.06 | $3.57M | |
-1.85 | $135.24M | |
-2.78 | $331.91M | |
-3.29 | $207.06M | |
-5.16 | $739.49M | |
4.11 | $2.77B | |
-16.32 | $5.25B | |
0.14 | $216.05M | |
-12.21 | $2.99B | |
-1.13 | $262.95M | |
-0.75 | $64.56M | |
-3.99 | $696.21M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AlloVir, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AlloVir, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is AlloVir, Inc.'s PE Ratio?
How is the PE Ratio calculated for AlloVir, Inc. (ALVR)?
What is the highest PE Ratio for AlloVir, Inc. (ALVR)?
What is the 3-year average PE Ratio for AlloVir, Inc. (ALVR)?
What is the 5-year average PE Ratio for AlloVir, Inc. (ALVR)?
How does the current PE Ratio for AlloVir, Inc. (ALVR) compare to its historical average?